Juvenile idiopathic arthritis

Disease ID:1222
Name:Juvenile idiopathic arthritis
Associated with:0 target
3 immuno-relevant ligands
Synonyms
JIA
Description
A family of inflammatory joint conditions with varying symptoms and severity, with onset before age 16. Includes oligoarthritis, polyarthritis, enthesitis-related JIA, psoriatic arthritis and Systemic-onset JIA.

Targets

No target related data available for Juvenile idiopathic arthritis

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
etanercept
Immuno Disease Comments: Approved drug for severe JIA.
Clinical Use: Used to treat severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis. | View clinical data
ibuprofen
Immuno Disease Comments: Approved NSAID used for many inflammatory conditions including JIA.
Clinical Use: Ibuprofen is used widely for its analgesic and antipyretic actions. | View clinical data
methotrexate
Immuno Disease Comments: Oral solution of methotrexate approved for JIA in pediatric pateints.
Clinical Use: Anti-tumour agent used in the treatment of acute lymphocytic leukemia (ALL), meningeal leukemia, non-Hogkin's lymphoma, breast, lung and head and neck cancers. Also indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole, and in the treatment of autoimmune conditions including severe psoriasis and rheumatoid arthritis. The first oral methotraxate solution (Xatmep®) was FDA approved in April 2017 for the treatment of ALL and polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients. A 2017 a paper reported that a combination of methotrexate with leflunomide relieves the immune defects and ameliorates symptoms of rheumatoid arthritis [1]. | View clinical data

References

Show »

1. Zhong W, Zhao L, Liu T, Jiang Z. (2017) IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide. Sci Rep, 7: 41143. [PMID:28117352]